常见妇科恶性肿瘤的筛查策略与影像整合
本文总结宫颈癌、子宫内膜癌和卵巢癌的现行及新兴筛查策略。宫颈癌一般风险人群采用细胞学检查和高危型HPV检测,子宫内膜癌和卵巢癌不推荐对一般风险人群进行常规人群筛查。影像主要用于筛查阳性或症状、查体、实验室异常后的检出、分期、治疗规划与随访,并经阴道超声用于部分高危人群的筛查评估。
要点
- 宫颈癌一般风险人群筛查依靠细胞学和高危型HPV检测,影像不用于初级筛查。
- 子宫内膜癌和卵巢癌一般风险人群不推荐常规人群筛查,以症状为导向评估。
- 经阴道超声主要用于Lynch综合征等高风险人群子宫内膜评估及少数高危人群卵巢癌筛查。
核心结论
- 影像在常见妇科恶性肿瘤初级筛查中的作用有限,通常在筛查阳性或异常实验室结果后进入诊疗流程。
- 宫颈癌一般风险人群采用细胞学检查和高危型HPV检测进行筛查,高风险人群适用调整后的指南。
- 不推荐对一般风险人群进行子宫内膜癌和卵巢癌的常规人群筛查,评估由症状驱动。
- 经阴道超声用于高风险人群的子宫内膜癌筛查及选择性的卵巢癌筛查,常与血清生物标志物检测联合使用。
研究设计与样本
- 本文为Radiographics发表的综述,总结宫颈癌、子宫内膜癌和卵巢癌的现行及新兴筛查策略及影像在筛查流程中的整合。
关键影像表现/征象
- 经阴道超声通过评估子宫内膜厚度用于高风险人群的子宫内膜癌筛查。
- 当根据症状、体格检查或异常实验室结果怀疑妇科恶性肿瘤时,影像用于病灶检出和定性、分期、治疗规划及治疗后监测。
诊断标准与关键数值
- 宫颈癌一般风险人群筛查包括细胞学分析和高危型HPV检测。
- 宫颈癌高风险人群包括HIV感染、慢性免疫抑制、高级别宫颈上皮内瘤变病史、既往HPV相关下生殖道恶性肿瘤或宫内暴露于己烯雌酚者。
- 子宫内膜癌高风险人群包括Lynch综合征患者,筛查包括临床评估和经阴道超声评估子宫内膜厚度。
- 卵巢癌高风险人群包括BRCA基因突变携带者,经阴道超声筛查和血清生物标志物检测适用于选择推迟降低风险的双侧输卵管卵巢切除术的患者。
- 影像表现被逐步整合入国际妇产科联盟宫颈癌和子宫内膜癌分期系统中。
临床应用与阅片要点
- 影像科医师应了解影像不用于一般风险人群常见妇科恶性肿瘤的初级筛查,避免过度筛查相关影像解读。
- 对筛查阳性或症状、查体、实验室异常的患者,重点关注病灶检出、局部分期、淋巴结状态及远处转移征象。
- 报告宫颈癌和子宫内膜癌时应熟悉国际妇产科联盟分期系统,将影像表现与分期条目对应。
- 对Lynch综合征等高风险患者行经阴道超声时,应规范测量并报告子宫内膜厚度。
局限性
- 原文为综述,未提供原始系统检索策略和纳入排除标准。
- 未报告具体影像诊断敏感度、特异度、AUC或阈值等定量指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Gynecologic malignancies, including cervical, endometrial, and ovarian cancers (the most common), are a substantial cause of cancer-related morbidity and mortality worldwide, with the prognosis linked to the stage at diagnosis. The aim of screening is to help detect premalignant or early-stage malignant lesions to reduce mortality. Imaging has a limited role in primary screening for the most common gynecologic cancers and usually enters the patient care workflow after a positive screening test or abnormal laboratory results are obtained. Population-level screening for cervical cancer in individuals at average risk involves cytologic analysis and testing for high-risk human papillomavirus (HPV), with modified guidelines for patients at increased risk (ie, those with HIV infection, chronic immunosuppression, a history of high-grade cervical dysplasia, prior HPV-related lower genital tract malignancies, or in utero exposure to diethylstilbestrol [DES]). Routine population-level screening for endometrial and ovarian cancers in patients at average risk is not recommended; evaluation is driven by symptoms. Screening for endometrial cancer in patients at risk (eg, those with Lynch syndrome) includes clinical evaluation and assessment of endometrial thickness at transvaginal US. US-based screening for ovarian cancer in individuals at high risk (eg, those with BRCA gene mutations) is reserved for selected patients (eg, those who defer risk-reducing bilateral salpingo-oophorectomy), who undergo transvaginal US screening and serum biomarker level testing. When gynecologic malignancy is suspected based on symptoms, physical examination, or abnormal laboratory results, imaging aids in lesion detection and characterization, staging, treatment planning, and posttreatment surveillance. Imaging findings are increasingly integrated into formal staging systems, including the International Federation of Gynecology and Obstetrics classification system for cervical and endometrial cancer, which highlights the radiologist's role in multidisciplinary care. The authors summarize current and emerging screening strategies for cervical, endometrial, and ovarian cancers and the integration of imaging into the screening workflow. ©RSNA, 2026 Supplemental material is available for this article.
引用
- Jha, Nougaret, Iranpour, et al. Screening for Common Gynecologic Malignancies. Radiographics. 2026. PMID: 42821448. doi:10.1148/rg.260031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。